Nonprofit, nonpartisan journalism. Supported by readers.


Medtronic claims clinical win for heart failure technology

When an aging or damaged heart can’t efficiently pump blood throughout the body, fluid can accumulate in the person’s lungs, signaling more serious heart failure.

At-risk patients typically weigh themselves daily, looking for sudden increases in weight that might reflect a build-up of fluid in their chests. Now, Medtronic says it has a more effective way to detect worsening heart failure.

OptiVol Fluid Status Monitoring is a feature of Medtronic’s implantable defibrillators. It uses electronic pulses to detect the amount of fluid in a person’s chest.

The company announced today that a clinical study of OpitVol found that the technology detected 76 percent of heart failure events, compared with 23 percent detected by weight measurements alone.

Also: The U.S. Food and Drug Administration has announced a Class 1 recall related to a Medtronic catheter kit. The label wrongly states that it is compatable with one of the company’s pump products.

No comments yet

Leave a Reply